Abstract
Background Endovascular treatment (EVT) is widely accepted for intracranial aneurysms due to its safety and efficacy. However, EVT of ruptured very small intracranial aneurysms (RVSIA) (≤3 mm) is still challenging and the risk-benefit ratio of EVT remains unclear. The aim of this study was to evaluate the safety and efficacy of EVT of RVSIA.
Methods We performed a systematic review and meta-analysis of the studies on EVT of RVSIA. Pooled prevalence rates were calculated for initial and follow-up complete occlusion rates (Raymond Roy Grade 1), recanalization, retreatment, long-term favorable outcome (modified Rankins scale score 0 to 2 or Glasgow Outcome Scale 4 or 5), procedure-related complications (coil herniation, thromboembolism, and intraprocedural re-rupture), and procedure-related mortality. Pooled odds ratios were calculated to compare these outcomes between simple coiling and stent-assisted coiling (SAC).
Results Of the 600 studies screened, 24 studies with a total of 1355 RVSIAs treated with EVT were included. The initial and follow-up complete aneurysm occlusion rates were 64% (95% confidence interval [CI]: 52–74%) and 85% (95% CI: 74–92%). The rates of recanalization and retreatment were 6% (95% CI: 3–10%) and 3% (95% CI: 2–4%). The favorable long-term follow-up outcome was observed in 91% (95% CI: 89– 93%) of patients. The rates of coil herniation, thromboembolism, and intraprocedural rupture were 2% (95% CI: 1–8%), 4% (95% CI: 3–6%), and 4% (95% CI: 2–7%), respectively. Mortality was 3% (95% CI: 2–4%). Comparison of outcomes between simple coiling and SAC revealed no significant difference, except for a higher likelihood of recanalization in the coiling group (Odds ratio, 3.51 [95% CI, 1.31–9.45]).
Conclusions Our meta-analysis demonstrates that EVT for RVSIA is a feasible, effective, and safe approach that is associated with favorable clinical outcomes in both the short and long term.
Competing Interest Statement
H. Matsukawa received a non-related lecture fee from Daiichi-Sankyo and consulting services fee from B. Braun. K. Uchida received a non-related lecture fee from Daiichi-Sankyo, Bristol-Myers Squibb, Stryker, and Medtronic. S. Yoshimura received a non-related lecture fee from Stryker, Medtronic, Johnson & Johnson, Kaneka Medics. A. Spiotta Research support (STAR) Avail, RapidAI, Penumbra, Microvention, Medtronic, Stryker, Brain Aneurysm Foundation. Consulting RapidAI, Avail, Penumbra, Medtronic.
Clinical Trial
NA
Clinical Protocols
NA
Funding Statement
Source of funding: None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NA
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data Availability
The data that support the findings of this study are available from the corresponding author, Alejandro M Spiotta, upon reasonable request.
